Physiologically based pharmacokinetic and biopharmaceutics modeling (PBPK/PBBM) are transforming drug development by reducing reliance on time-consuming and costly in vivo studies and accelerating decision-making. These modeling approaches provide a mechanistic framework to support drug development from discovery through formulation.

In this webinar, Deanna Mudie, Senior Principal Scientist of PBPK R&D at Simulations Plus, will explain how high-throughput PBPK using ADMET Predictor® can rapidly predict systemic exposure using in silico derived properties or minimal in vitro data, enabling more informed compound selection and reducing the need for extensive preclinical testing. She’ll also cover how in later stages, PBBM using GastroPlus® integrates drug and formulation properties with gastrointestinal physiology to simulate in vivo performance — supporting formulation optimization, food-effect prediction, and the development of clinically relevant dissolution specifications.

Whether you’re a modeler, formulation scientist, or development strategist, this session will provide real-world case studies demonstrating how integrating PBPK and PBBM across the drug development continuum can enhance productivity, reduce in vivo study requirements, and enable smarter, faster decisions.

Speakers:

• Deanna Mudie, Ph.D. – Senior Principal Scientist, PBPK R&D, Simulations Plus
• Robert Wenslow, Ph.D. – Co-Founder, Chief Business Officer, Crystal Pharmatech, Inc.